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Abstract: There is a wide variety of cancer types yet, all share some common cellular and 
molecular behaviors. Most of the chemotherapeutic agents used in cancer treatment are 
designed to target common deregulated mechanisms within cancer cells. Many healthy 
tissues are also affected by the cytotoxic effects of these chemical agents. Fucoidan, a natural 
component of brown seaweed, has anti-cancer activity against various cancer types by 
targeting key apoptotic molecules. It also has beneficial effects as it can protect against 
toxicity associated with chemotherapeutic agents and radiation. Thus the synergistic effect 
of fucoidan with current anti-cancer agents is of considerable interest. This review discusses 
the mechanisms by which fucoidan retards tumor development, eradicates tumor cells and 
synergizes with anti-cancer chemotherapeutic agents. Challenges to the development of 
fucoidan as an anti-cancer agent will also be discussed. 
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1. Introduction to Cancer 
Cancers are multifactorial diseases of various etiologies. They arise largely as a result of acquired 
genetic changes that alter cell function leading neoplastic cells to gain survival or growth  
advantages [1]. For cancer cells to survive, the generation of new blood vessels (angiogenesis) is 
required. Cancer leads to death mostly through tumor cell spread to distal organs (metastasis). Various 
pathways are disrupted in tumor development, which result from unbalanced programmed cell death, 
disordered signaling pathways, angiogenesis and poor immune response against cancer. Most of the 
chemotherapeutic agents used in cancer treatment target these major deregulated pathways. 
Unfortunately, as many of these therapies cause severe side effects, the toxicities limit the dose and 
thus the efficacy of treatment. Therefore, there is strong interest in developing better-tolerated  
anti-cancer agents. 
2. A Role for Natural Products for Cancer Treatment 
Chemotherapy has been a cornerstone of the standard cancer treatment regimens since the 1960s.  
A variety of chemicals ranging from traditional agents such as methotrexate and folic acid analogues to 
novel chemicals such as anthracyclines have been used in cancer treatment [2]. Despite promising 
tumor growth-inhibitory effects in pre-clinical tests, many fail in clinical trials when adverse unexpected 
side effects are revealed. Traditionally anti-cancer chemotherapy targets rapidly dividing and proliferating 
cells. Therefore, normal cells which have high-proliferating potential are also affected. 
Novel therapeutic agents are designed to target specific molecules (targeted therapy). However, these 
targeted therapies are not always completely free of side effects either. For instance, vemurafenib, a  
B-Raf enzyme inhibitor, is specific for oncogenic mutant V600E B-Raf positive melanoma cells. This 
drug was the first targeted molecular therapy, which was approved for use in advanced stages of 
melanoma. Although vemurafenib has shown significant beneficial anti-cancer effects, several studies 
have reported the rapid emergence of acquired resistance and adverse dermatological effects. It also 
stimulates B-Raf expression in V600E B-Raf negative patients promoting melanoma growth [3,4]. 
Monoclonal antibodies are another example of targeted therapy and are designed to specifically target 
the cancer antigens located on tumor cells. Monoclonal antibodies are generally safer than chemotherapy 
and the side effects caused by them include mild allergic reactions such as urticaria. But they can also 
cause severe reactions such as infusion reactions and serum sickness. As an example, rituximab  
(anti-CD20), which is widely used in treating B-cell lymphoma, generally causes only mild toxicities, 
however, reports have described occasional cases with severe complications such as anaphylactic reactions 
and myocardial infarction as well as high risk of tumor lysis syndrome in patients who have a high 
burden of tumor cells in their circulation [5]. 
Concerns over toxicity, tumor cell resistance and development of secondary cancers from 
chemotherapeutic chemicals have generated interest in exploiting natural products for cancer treatment. 
Flavopiridol is a flavonoid derived from the indigenous Indian plant Dysoxylum binectariferum, which 
inhibits cell cycle progression. It is the first cyclin-dependent kinase (CDK) inhibitor to be approved 
for use in clinical trials [6]. Natural products are also being tested as adjuvants for use in synergy with 
chemotherapeutic agents. For example those with immunomodulatory effects can reduce immune 
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suppression and the associated increased risk of infection. In George et al. [7] study, Indukantha 
Ghritha (IG), a polyherbal preparation consisting of 17 plant components, was used as an adjuvant to 
cyclophosphamide cancer chemotherapy and shown to stimulate the hematopoietic system and induce 
leukopoiesis in tumor-bearing mice. When administrated in combination with cyclophosphamide, it 
reversed myelosuppression induced by cyclophosphamide suggesting its potential to minimize or 
reverse chemotherapy-induced leukopenia. 
Polysaccharides include a large family of diverse biopolymers. They are constituted by 
monosaccharide residues linked together by O-glycosidic bonds that are found in natural and  
semi-synthetic structures [8]. Due to structural diversity, polysaccharides display the highest biological 
properties among macromolecules. Many natural polysaccharides obtained from natural sources such as 
plants and algae have anti-cancer properties. The multifunctional structure of natural polysaccharides 
also allows them to be used in conjugation with anti-cancer agents that lack physiochemical and 
biopharmaceutical properties [8,9]. 
3. Fucoidan 
Fucoidan is a natural sulfated polysaccharide that exists mainly in the cell wall matrix of various 
species of brown seaweed such as mozuku, kombu, limumoui, bladderwrack and wakame [10]. Various 
forms of fucoidan have also been recognized in some marine invertebrates such as sea urchins [11] and 
sea cucumbers [12]. The brown seaweeds containing fucoidan are widely consumed as part of the 
normal diet in East Asia, particularly Japan, China and Korea. 
3.1. Fucoidan’s Anti-Cancer Potential 
The anti-cancer property of fucoidan has been demonstrated in vivo and in vitro in different types of 
cancers. Nevertheless, it has been rarely investigated for its anti-cancer properties in clinical trials. 
Fucoidan mediates its activity through various mechanisms such as induction of cell cycle arrest, apoptosis 
and immune system activation. Additional activities of fucoidan have been reported that may be linked to 
the observed anti-cancer properties and these include induction of inflammation through immune system, 
oxidative stress and stem cell mobilization. These activities have been reviewed by Kwak [13]. 
3.1.1. Fucoidan and Cell Cycle 
Fucoidan treatment results in sub G0/G1 cell accumulation (suggestive of dead cells/apoptotic cells) 
in a variety of cell types [14,15]. It can also induce cell cycle arrest in other phases; Riou et al. [16] 
and Mourea et al. [17] reported arrest in G1 phase in a chemo-resistant non-small-cell bronchopulmonary 
carcinoma line by fucoidan from Ascophyllum nodosum and Bifurcaria bifurcate, respectively. 
In an investigation of the mechanism of the action, fucoidan demonstrated significant down 
regulation of cyclin D1, cyclin D2 and CDK4 in cancer cells [18–20]. The crude fucoidan from Fucus 
vesiculosus increased the level of p21/WAF1/CIP1 in PC3 cells and down-regulated E2F; a 
transcription factor that controls progression of cells from G1 to S phase [18]. 
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Table 1. Effects of fucoidan on cell cycle and apoptosis molecules. 
Ref Cell Type Fucoidan Source Dose (µg/mL) Effects on Cell Cycle Effects on Apoptosis Pathways Extrinsic Intrinsic Common  
[15] 
Human lymphoma 
HS-sultan cells 
F. vesiculosus  100 
 ↑ sub G0/G1 
-  ↓ MMP  Caspase 3 activation 
 No G0/G1 or G2/M arrest 
[20] 
HTLV-1 infected  
T-cell HUT-102- cells 
C. okamurans 3000 
 G1 arrest 
Apoptosis was reversed by 
caspase 8 inhibitor 
 Caspase 9 activation 
 Apoptosis was reversed by 
caspase 3 inhibitor 
 ↓ cyclin D2, c-myc  No changes in Bcl-2 and Bcl-XL 
 No changes in p21,p53  ↓ survivin, cIAP-2 
[21] 
Human hepatocellular 
carcinoma cells 
Okinawa mozuku 22.5 
 ↑ G2/M phase in HAK-1A,  
KYN-2, KYN-3 cell lines 
-  No clear caspase 9 activation in HAK-1B cell line 
 No clear caspase 3 activation in 
HAK-1B cells 
[22] 
Human breast cancer 
MCF7 cells 
Not mentioned 1000  ↑ sub-G1 fraction 
 Caspase 8 activation  Caspase 9 activation  Caspase 7 activation 
 Caspase inhibitors blocked 
apoptosis completely 
 ↓ Bid, cytosolic Bax 
 PARP cleavage 
 ↑ whole lysate Bax, cytosolic cytochrome C 
[23] 
Human acute leukemia 
NB4 and HL-60 cells 
F. vesiculosus  150  ↑ sub-G1 fraction  Caspase 8 activation 
 caspase 9 activation  PARP cleavage  
 No changes in Bcl-2 or Bax 
 Caspase 3 activation 
 ↓ Mcl-1, ↑ cytochrome C 
[24] 
Human colon  
cancer HT-29 and 
HCT116 cells 
F. vesiculosus   - 
 Caspase 8 activation  Caspase 9 activation  PARP cleavage  
 ↑ Fas, DR5, TRAIL  ↑ cytochrome C, Smac/Diablo, Bak, t-Bid 
 Caspase 3 and 7 activation  No significant effects on 
FasL and DR4 
 No changes in Bcl-2, Bcl-xL, Bax, Bad, Bim, Bik 
 ↓ XIAP, survivin 
[25] 
Human lung cancer 
A549 cells 
U. pinnatifida 50, 100, 200  ↑ Sub-G1frction - 
 Caspase-9 activation  ↓ procaspase-3 
 ↓ Bcl-2, ↑ Bax  PARP cleavage 
[14] 
Human breast cancer 
MCF-7 cells 
Cladosiphon 
novae-caledoniae 
82, 410, 820 
 ↑ Sub-G1 
 No changes in caspase-
8 
 Mitochondrial dysfunction  No activation of PARP and 
caspase-7 
 No significant changes in cell  
cycle distribution 
 AIF and cytochrome C release 
 No cleavage of caspase-9 and Bid.  All caspase inhibitors failed to 
attenuate FE-induced apoptosis  ↓ Bcl-2, Bcl-xl ,↑ Bax, Bad 
[26] Hela cells 
Sargassum 
filipendula 
1500 - - 
 No effect on caspase 9 activation  No effect on caspase 3 
(Caspase independent)   ↑ cytosol AIF 
[19] 
Human breast cancer 
MCF-7 cells 
F. vesiculosus 400, 800, 1000 
 G1 phase arrest 
 Caspase-8 activation 
 ↓ Bcl-2 
 Caspase-dependent pathway   ↑ Sub G0/G1 ↓ cyclin D1 and  
CDK-4 gene expression 
 ↑ Bax 
 Release of cytochrome C and APAf-1 
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Table 1. Cont. 
Ref Cell Type Fucoidan Source Dose (µg/mL) Effects on Cell Cycle Effects on Apoptosis Pathways Extrinsic Intrinsic Common  
[18] 
Human prostate cancer 
PC-3 cells 
U. pinnatifida 100 
 G0/G1 phase arrest 
 DR5, caspase-8 
activation 
 ↓ Bcl-2  Caspase-3 activation 
 ↓ E2F-1  ↑ Bax, 
 PARP cleavage 
 ↑ p21Cip1/Waf  Caspase 9 activation 
[27] 
Human Hepatocellular 
Carcinoma  
SMMC-7721 cells 
U. pinnatifida 1000 
 Non-significant accumulation  
in S-phase 
 Caspase-8 activation 
 Caspase-9 activation 
 Caspase-3 activation 
 MMP dissipation, Cytochrome C release 
 ↓ Bcl-2, ↑ Bax 
 ↓ XIAP, livin mRNA expression 
[28] 
Human bladder 
carcinoma 5637 and 
T-24 cells 
F. vesiculosus  100 
 ↑ G1-phase, p21WAF1 
- - - 
 ↓ Cyclin E, D1, DK2, CDK4 
 No change in p27KIP,p53 
 ↑ p21WAF1 and CDK4 binding 
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In a recent study, fucoidan down-regulated cyclin E, CDK2, CDK4 resulting in G0/G1 arrest in 
human bladder cancer 5637 cells. Furthermore, immunoprecipitation assays revealed a significant 
increase in the binding of p21/WAF1/CIP1 to CDK2 and CDK4 in cells treated with fucoidan, 
suggesting that the induced G0/G1 arrest is due to suppression of CDK activity following direct 
binding of this CDK inhibitor to CDKs 2 and 4 [28]. Table 1 summarizes findings of studies 
examining the effects of fucoidan on cell cycle. 
3.1.2. Fucoidan and the Apoptosis Pathway 
Apoptosis characterized by cytoplasmic shrinkage and chromatin condensation facilitates the 
removal of cells without inducing inflammation [29]. Apoptosis occurs through either the extrinsic 
(cytoplasmic) pathway whereby death receptors trigger the apoptosis, or the intrinsic (mitochondrial) 
pathway in which changes in mitochondrial membrane potential (MMP) lead to cytochrome C release and 
death signal activation. Both pathways activate executive caspases that cleave regulatory and structural 
molecules [30]. Several studies examining a variety of cancers such as hematopoietic, lung, breast and 
colon cancers have shown that fucoidan-mediated cell death occurs through triggering apoptosis 
(Table 1) [14,22,24]. A very low dose of fucoidan from F. vesiculosus (20 µg/mL) activated common 
caspases 3 and 7 in human colon cancer cells [24], whereas it induced the same activity in T-cell 
leukemia at a much higher concentration (3 mg/mL) [20]. Caspase 8 and 9, two of the best characterized 
molecules of the extrinsic and intrinsic pathways respectively are activated by fucoidan [24]. 
Yamasaki-Miyamoto et al. showed that pre-treatment with caspase 8 inhibitor completely blocked 
fucoidan mediated apoptosis in MCF-7 breast cancer cell line [22]. In contrast, in Zhang et al. [14] study, 
the mediated apoptosis by fucoidan from Cladosiphon okamuranus in MCF-7 human breast cancer cell 
line was shown to be caspase independent. As cytochrome C and apoptosis inducing factor (AIF) 
increased in the cytosol, it was concluded that fucoidan performed its activity through mechanisms 
altering mitochondrial function. 
Fucoidan also affects other components of extrinsic and intrinsic pathways. Analyzing the extrinsic 
pathway, 20 µg/mL crude fucoidan from F. vesiculosus increased the levels of the death receptors Fas, 
DR5 and TRAIL but not FasL and DR4 in human colon cancer cell lines [24]. Bcl-2 family members 
include anti-apoptotic, pro-apoptotic and regulatory proteins, which are mainly involved in the 
apoptosis intrinsic pathway. Contradictory results have been described in the expression of these regulatory 
molecules in response to fucoidan (Table 1). Treatment of MDA-MB231 breast cancer cells with  
820 µg/mL of low molecular weight (LMW) fucoidan resulted in a significant decrease in  
anti-apoptotic proteins Bcl-2, Bcl-xl and Mcl-1 [31]. In contrast, no changes in expression of Bcl-2, 
Bcl-xl, Bad, Bim and Bik were observed in colon cancer cells when they were treated with 20 µg/mL 
fucoidan from Fucus vesiculosus [24]. Taken together, the results suggest that fucoidan may interact 
with several components of the apoptosis pathway. 
3.1.3. Fucoidan and Angiogenesis 
Fucoidan inhibits the formation of new vessels by which tumor cells receive their oxygen and 
required nutrients. Fucoidan has been found to inhibit the binding of VEGF, a key angiogenesis promoting 
molecule, to its cell membrane receptor [32]. Xue et al. examined the anti-angiogenic properties of 
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fucoidan in 4T1 mouse breast cancer cells both in vitro and in vivo and observed a significant  
dose-dependent decrease in VEGF expression in cells treated with fucoidan. Further, in a mouse breast 
cancer model using 4T1 cells, intraperitoneal injections of 10 mg/kg body weight fucoidan from  
F. vesiculosus for 20 days markedly reduced the number of microvessels. Using immunohistochemistry, 
fucoidan was shown to reduce VEGF expression compared to the control group [33]. In contrast, Zhu 
et al. reported that fucoidan did not suppress angiogenesis and VEGF expression in human 
hepatocarcinoma cell lines treated with 10 to 200 µg/mL of a commercial fucoidan purified from 
Sargassum spp. Similarly no changes in VEGF expression were observed in xenograft tumors developed 
in nude mice following 20 to 200 mg/kg/body weight fucoidan injected intraperitoneally once a day over 
25 days [34]. It is postulated that different effects are observed with fucoidans of various MWs and 
molecular structures and this is reviewed by Kwak [13]. 
3.1.4. Fucoidan and Metastasis 
In 1987, Coombe et al. demonstrated that fucoidan significantly decreased tumor cells metastasis to 
the lungs in animals that were intravenously injected with rat mammary adenocarcinoma 13762 MAT 
cells [35]. It was first reported that fucoidan inhibits cell invasion through competing with tumor cell 
binding with laminin in the basement membrane [36]. Subsequent studies then revealed that fucoidan 
binds to fibronectin with high affinity and prevent attachment of tumor cells. In agreement with this 
study, fucoidan reduced the spread of human breast adenocarcinoma cells plated on a surface containing 
fibronectin [37]. 
Selectin inhibition by fucoidan interferes with tumor cell–platelet interaction. In Cumashi et al.  
study [38], highly metastatic MDA-MB-231 breast cancer cells were plated in platelet-coated plates in 
the presence or absence of 100 µg/mL fucoidan. The number of cells attached to the platelets 
decreased by 80% in the presence of fucoidan. Interaction of tumor cells with platelets is one of the 
key factors in facilitating the early steps of tumor cell migration. During tumor cell migration, most 
circulating tumor cells do not survive attack from immune cells or the shear forces of the blood stream. 
However, they can attach to platelets to induce platelet aggregation allowing the tumor cell cluster to 
survive in the micro-vascular system. It was concluded that fucoidan inhibited P-selectin residing on 
the platelet surface and led to reduced number of attached tumor cells. Fucoidan can also inhibit other 
adhesion molecules such as integrins residing on the tumor cell surface and can modify distribution of  
their subunits. 
Tumor invasion requires the secretion of proteolytic enzymes by tumor cells to break down  
the extracellular matrix (ECM) proteins (e.g., collagen, fibronectin and laminin), with the matrix 
metalloproteinases (MMPs) MMP-2 and MMP-9 playing a major role. Fucoidan attenuates both 
expression and activity of these enzymes [39]. 
3.1.5. Fucoidan and Signaling Pathways 
The extracellular signal-regulated kinase (ERK) pathway (or Ras/Raf/MAPK pathway) is often 
hyperphosphorylated and upregulated in a variety of human cancers. The potential for developing 
anticancer agents that cause ERK’s dephosphorylation and pathway blockade have been explored. 
Various studies have shown that fucoidan inhibits tumor cell proliferation by decreasing ERKs activity 
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through reduction of its phosphorylation [15,40] while several studies have proposed that fucoidan 
causes ERK activation rather than inactivation [41,42]. To explain these contradictions, it should be 
noted that the ERK signaling pathway is highly complex. It induces a range of different responses 
including cell proliferation, differentiation, migration and apoptosis depending on cell type, the type of 
stimulus and duration of activation [43]. Therefore, some of the contradictory results of the 
aforementioned studies can be explained by different fucoidan extracts with different molecular 
structures being used on different tumor cell types. Another complication is that different studies have 
examined ERK phosphorylation over different time periods ranging from 10 min to 48 h. Jin et al. 
reported increased ERK1/2 phosphorylation in HL-60 leukemic cell line 10–15 min after fucoidan 
treatment. The phosphorylation returned to the basal level after 1 h [23]. In Lee et al. study, crude 
fucoidan progressively diminished phosphorylation of ERK1/2 from 1 h to 9 h after treatment [39]. 
JNK and p38 are other MAPK superfamily members whose activity is altered by fucoidan. 
Fucoidan induced cell death in breast cancer cells through phosphorylation and activation of JNK and 
p38 after 30 min. The fucoidan-induced apoptosis significantly annulled in the presence of JNK 
inhibitor, indicating critical role of JNK in fucoidan-mediated apoptosis [14]. 
 
Figure 1. Overview of main signal transduction pathways involved in cell proliferation and apoptosis.  
Similarly, the PI3K/AKT, GSK and Wnt pathways have been shown to be triggered by fucoidan. 
PI3K/AKT pathway generally inhibits apoptosis. AKT over-activation is also associated with drug 
resistance and tumor cell survival. As a result, deactivating this pathway could be another potential 
target for anti-cancer drug development. Most of the studies have reported inactivation of AKT by 
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fucoidan. PI3k, an upstream molecule of AKT, is also inhibited by fucoidan [39]. Upregulation of the 
Wnt signaling pathway is believed to have a critical role in prostate cancer development, survival and 
progression. Fucoidan from F. vesiculosus activated GSK-3β in PC3 human prostate cancer cells 
resulting in hypo-phosphorylation and inactivation of β-catenin, a critical component of the Wnt pathway 
(Figure 1) [18]. Figure 1 represents an overview of the mentioned signaling pathways. 
3.1.6. Fucoidan and the Immune System 
The effects of fucoidan on molecules of the immune system have been studied both in vitro and  
in vivo and effects on both cellular and humoral elements have been described. Fucoidan increases 
both activity and number of natural killer (NK) cells in vivo [44,45]. Increase in the number of 
cytotoxic T-cells (CTLs) has also been reported. A high-molecular-weight (HMW) fucoidan from 
Cladosiphon okamuranus (200–300 kDa) induced a large increase in the proportion of murine 
cytotoxic T cells [46]. Investigation of the role of fucoidan on dendritic cell (DC)-mediated T-cell 
cytotoxicity has revealed that the stimulation of CTLs was more effective in fucoidan-treated DCs as CTLs 
co-cultured with fucoidan-treated DCs exerted a high level of specific lysis of breast cancer cells [47]. 
In a recent study, the role of fucoidan in DCs function and its adjuvant effect have been examined  
in vivo. Fucoidan was systemically administrated to mice by intraperitoneal injection. Examination of 
the spleen DCs revealed up-regulation of maturation markers as well as production of IL-6, IL-12 and 
TNF-α. Fucoidan was then used as an adjuvant in vivo with ovalbumin antigen and induced Th1 
mediated immune response and CTL activation [48].  
3.1.7. Fucoidan and Malignant Transformation in Vitro and in Vivo 
Few studies have reported the potential of fucoidan to inhibit neoplastic transformation. Teas et al. fed 
rats with dietary seaweed (Laminira) for 55 days and administrated the carcinogen 7,12-dimethylbenz(a) 
anthracene intragastrically. Following 26 weeks monitoring, experimental rats showed a significant 
delay in the median time for tumor appearance (19 vs. 11 weeks in the control group) [49]. 
Transforming growth factor β1 (TGFβ1) is believed to promote tumor development and metastasis 
through epithelial to mesenchymal transition (EMT), a process that enables epithelial cells migrate to 
distant areas during late stages of breast cancer development [50]. To trigger tumor progression, 
TGFβ1 recruits TGF receptors (TGFR) residing on the cell surface. The investigations of effects of 
fucoidan on TGFβ1-promoted carcinogenesis in MDA-MB-231 breast cancer cells have indicated that 
fucoidan decreased the expression of TGFRs and affected the downstream signaling molecules, which 
are involved in TGFβ1-mediated EMT [41].  
Epidermal growth factor (EGF) is another carcinogenesis promoter, which induces tumor 
transformation through overexpression and activation of EGF receptor (EGFR). EGFR has a key role 
in cell proliferation and differentiation and many carcinomas arise from its mutations [51].  
Lee et al. examined the role of fucoidan on the activation of EGFR and EGF-mediated neoplastic 
transformation [52]. They utilized murine JB6 Cl41 epidermal cells and induced cell transformation by 
EGF in the presence of fucoidan from L. guryanovae. Fucoidan markedly reduced the EGFR activation 
through hypo-phosphorylation. It also inhibited EGF-tumorigenic activity through inhibition of AP-1, a 
transcription factor responsible for cell proliferation regulation. 
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3.2. Fucoidan Metabolism 
Fucoidanase, the enzyme responsible for fucoidan hydrolysis, has only been found in brown 
seaweed and marine microorganisms such as some marine bacteria and fungi [53] and not in humans. 
It is possible that the acidic conditions in the stomach could degrade fucoidan, but it has been reported 
that the low gastric pH does have restricted effects on fucoidan [54]. 
Small amounts of dietary fucoidan can be endocytosed and cross the intestinal wall directly without 
breaking down [54]. In Tokita et al. study, 10 volunteers were given oral fucoidan and the 
concentrations of fucoidan in the serum and urine were analyzed. Fucoidan was detectable 3 h after 
administration and increased to 100 ng/mL in serum and 1000 ng/mL in urine. However the rate of 
absorption in the small intestine was highly variable among the participants. The MW of fucoidan in 
serum was similar to administered fucoidan indicating that fucoidan was not hydrolyzed by digestive 
enzymes [55]. However, the MW of the fucoidan detected in urine was significantly smaller than the 
ingested fucoidan suggesting that fucoidan is degraded in the excretory system and possibly the kidney 
and not by intestinal enzymes or normal flora. 
To evaluate the fucoidan uptake process by cells, the internalization of LMW fucoidan into rabbit 
smooth muscle cells (SMCs) was analyzed. Fucoidan was shown to be internalized by endocytosis at 6 h. 
The number of vesicles containing fucoidan increased in the peri-nuclear region at 24 h, but nuclear 
internalization was not observed at any time during the study [56]. However, examining the transport 
of a native fucoidan from Cladosiphon okamuranus with MW of 80 kDa revealed a poor permeation of 
fucoidan across the human colon adenocarcinoma Caco-2 cell monolayer [57]. 
Regarding the specific ligands by which fucoidan binds to the cells surface, several molecules have been 
implicated including class A macrophage scavenger receptors for fucoidan attachment to macrophages [58] 
as well as adhesion molecules such as L-selectin and P-selectin [59] and integrins [60]. However, some 
reports have shown fucoidan mediates apoptosis through selectin-independent mechanisms [15]. 
3.3. Fucoidan as a Synergistic Anti-Cancer Agent 
The ability of fucoidan to synergize with standard anti-cancer agents and/or reduce toxicity has 
recently been investigated. Ikeguchi et al. examined the synergistic effect of a HMW fucoidan with 
colorectal cancer chemotherapy agents; oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) or 
irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI). The test patients received 150 mL/day for  
6 months of liquid that contained 4.05 g fucoidan. From the commencement of chemotherapy, toxicities 
and chemotherapy efficiency were compared. Fucoidan showed no side effects such as allergic 
dermatitis. Diarrhea, neurotoxicity and myelosuppression were not suppressed by fucoidan, whereas 
general fatigue was significantly decreased from 60% to 10%. The patients were followed for 
approximately 15 months and the survival rate of the patients who received fucoidan was longer than 
that of the control participants; however the difference was not significant, probably due to the small 
numbers [61].  
Fucoidan affects the migration and invasion of multiple myeloma (MM) cells treated with 
chemotherapy drug cytarabine. The human myeloma cell lines RPMI8226 and U266 were treated with 
crude fucoidan from F. vesiculosus for 72 h and then cytarabine for 6 h. Fucoidan reduced cell migration 
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through a Boyden chamber and down-regulated expression of CXCR4 and MMP-9 [62]. Fucoidan 
from Saccharina cichorioides has been reported to synergize with the anti-tumor activity of low dose 
resveratrol (a natural polyphenol extracted from foods and beverages) on invasive and highly motile 
HCT 116 colon cancer cell line [63]. In the colony formation assay, fucoidan plus resveratrol reduced the 
colony number by 60% compared to 34% and 27% in resveratrol alone or fucoidan alone, respectively.  
Zhang et al. studied the combinatory effect of fucoidan and three commonly used anti-cancer 
agents; cis-platin (CDDP), tamoxifen (TAM) and paclitaxel (Taxol) on signal transduction pathways. 
Fucoidan from Cladosiphon navae-caledoniae plus anti-cancer agents reduced the ERK phosphorylation in 
MDA-MB-231 breast cancer cells compared to untreated control or fucoidan alone [64]. Dietary 
fucoidan synergistically reduced cell growth in the OE33 cell line when it was combined with 
lapatinib, a targeted therapy that acts as a tyrosine kinase inhibitor in advanced HER2-positive breast 
cancer cells [65].  
In a xenograft transplantation study, the effect of fucoidan alone or in combination with 
cyclophosphamide was examined on tumor growth. Nine days after the injection of Lewis lung 
carcinoma cells into mice, fucoidan from Fucus evanescens was administered to animals alone or 
combined with cyclophosphamide. The fucoidan group showed marked antitumor (33% tumor growth 
inhibition) and anti-metastatic (29% reduction of the number of metastases) activities. However, 
fucoidan did not exhibit a synergistic effect with cyclophosphamide on tumor growth, but significantly 
decreased the lung cancer cells metastasis [66]. 
3.4. Why Fucoidan Usage is Complicated? 
Despite the promising results about the anti-cancer effect of fucoidan, there are still challenges 
impeding utilization of fucoidan in the clinic. Variable and contradictory results being influenced by 
endogenous and exogenous factors in fucoidan usage are of the main concerns. In this section we will 
summarize important conditions, which have been undertaken in different experiments and have led to 
such variable results in reported studies. 
3.4.1. Structure and Molecular Weight Variation 
Fucoidan is composed of α-(1-2) or α-(1-3)-linked L-fucose with a fucose content of 34-44%. It 
also contains various amounts of other monosaccharaides such as galactose, mannose, xylose and 
uronic acid all of which make up less than 10% of the total fucoidan structure [67,68]. The sulfate 
groups in fucoidan structure are mainly at position 4 but they can also occupy position C2 and 
occasionally C3 [53]. The fucoidan structure and monosaccharide composition vary depending on 
different factors such as the source of fucoidan, the time and location of harvesting and the extraction 
method, which can affect the fucoidan’s bioactivities. Most anti-cancer studies of fucoidan have used a 
commercially available crude fucoidan extracted from Fucus vesiculosus (Sigma Co. St. Louis, MO, 
USA). Some groups have extracted and purified fucoidan in their own laboratories. Okinawa mozuku,  
C. Okamuranus tokida, Sargassum sp. and Undaria pinnatifida are the most common fucoidans 
examined in cancer studies.  
Cumashi et al. studied different biological aspects of fucoidan from nine different species of brown 
seaweed in rats [38]. Analysis of P-selectin-mediated neutrophil adhesion to platelets revealed that 
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extracted fucoidans from only some sources like F. evanescens and A. nodosum could serve as more 
efficient P-selectin inhibitors. Furthermore, in contrast to other sources, fucoidan from C. okamuranus did 
not exert anti-coagulant activity, which was suggested to be due to high content of 2-O-a-D-glucuronyl 
substituent in the polysaccharide chain of fucoidan from C. okamuranus. 
Sulfation is another key factor in fucoidan bioactivity. More sulfation is linked with greater 
bioactivity and thus researchers have produced over-sulfated fucoidans to enhance its biological 
properties [36]. It has been suggested that over-sulfation causes higher negative charge in the molecule 
which can facilitate formation of fucoidan-protein complexes involved in cell proliferation [69].  
Molecular weight is another crucial factor in fucoidan activity. Cho et al. produced three fucoidan 
fractions with molecular weights of <5, 5–30 and >30 kDa and reported that the F5-30K showed the 
most tumor growth inhibitory effect despite the sulfate amount in F<5K being greater than in the two 
other fractions [70].  
The extraction method can also affect fucoidan’s bio-properties. Fucoidan from Undaria pinnatifida 
was hydrolyzed using different hydrolysis conditions and their anti-cancer activity was compared  
in vitro. The native fucoidan showed 37% anti-cancer activity; hydrolyzed fucoidan generated under mild 
conditions (in boiling water with HCl for 5 min) exhibited 75.9% anti-tumor activity; whereas 
hydrolyzed fucoidan generated under harsh conditions (microwave for more than 90 s) slightly 
enhanced the anti-cancer effect [71]. 
3.4.2. Fucoidan Dose and Route of Administration 
As fucoidan is a large highly branched molecule, the dosage for in vitro studies mostly resides in 
the range of µg/mL and not ng/mL. However, there is a large variation in the doses. Vischchuk et al. 
treated HCT-116 colon cancer cells with 100–800 μg/mL fucoidan from the brown alga Saccharina 
cichorioides Miyabe and observed that fucoidan exerted a low cytotoxicity and there was less than 
15% reduction in cell number with the high dose of 800 μg/ml after 24 h [63]. In contrast, Kim et al. 
demonstrated that 20 μg/mL fucoidan from F. vesiculosus caused 37% growth inhibition in the same cell 
line after 72 h [24]. Though the difference between incubation times (24 h vs. 72 h) should be 
considered, the dose difference (800 μg/mL vs. 20 μg/mL) was substantial. The source of fucoidan 
appears to be the main factor leading to variation in results. Though most researchers have utilized 
dosages of less than 1 mg/mL, there are reports of use of up to 3 mg/mL fucoidan. 
Regarding the in vivo studies, both dose and the route of administration can affect outcome. To 
select the most effective dose, mice were treated with various doses of fucoidan (10–400 mg/kg body 
weight) followed by total-body irradiation. The mice injected with 100 mg/kg body weight fucoidan 
showed the best survival rate at 30 days post-irradiation [72]. Other studies have used various doses 
ranging from 5 mg/kg to 100 mg/kg and occasionally doses up to 500 mg/kg/body weight of different 
fucoidan extracts. The amount and number of doses of fucoidan administration has also been shown to 
be important for in vivo studies. Alekseyenko et al. studied mice with lung carcinoma that were treated 
with fucoidan from Fucus evanescence. They found that a single injection of 25 mg/kg/body weight of 
fucoidan did not inhibit tumor cell proliferation, while three-time injections of 10 mg/kg/body weight 
significantly reduced tumor growth and metastasis [66]. Most in vivo studies of anti-tumor activity have 
selected intraperitoneal (IP) injections, but subcutaneous (SC) or intravenous (IV) routes of 
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administration have also been used. Oral fucoidan is another route for in vivo delivery either for its 
anti-tumor properties following tumor induction or as a neoplastic transformation inhibitor 
administered prior to cancer induction. Taken together, these studies indicate that different delivery 
routes can affect the fucoidan metabolism in vivo and lead to variable outcomes. 
3.5. Fucoidan Toxicity 
Whilst fucoidan consumed in food in the form of 4% of the total dry weight of brown seaweeds is 
generally regarded as safe, the fucoidan used for research is a highly purified extract. For in vitro 
studies, researchers have utilized normal cells such as normal fibroblasts alongside tumor cell lines and 
reported that fucoidan did not induce apoptosis within normal cells at the doses which were toxic for 
cancer cell lines. A very high dose of 3 mg/mL fucoidan suppressed the viability of peripheral blood 
mononuclear cells from healthy donors by 25% compared to 60%–90% in five different leukemic  
T-cells [20]. In vivo, oral administration of up to 1 g/mL/body weight Undaria pinnatifida fucoidan was 
non-toxic in mice but higher doses (2 g/mL/body weight) induced changes in thyroid weight and altered 
levels of triglyceride and alanine transaminase activity [73]. In another study, daily administration of 
300 mg/kg/body weight fucoidan from Laminaria japonica in Wister rats over 6 months did not induce 
any adverse side effects, but higher doses (900–2500 mg/mL) resulted in coagulopathy and markedly 
elevated clotting time [74]. 
Toxicity has also been examined in the context of fucoidan use as adjuvant. Oh et al. examined the 
combinatory effect of fucoidan with the standard anti-Her2 inhibitor lapatinib in different breast cancer 
cell lines in vitro [65] and found that fucoidan decreased the efficiency of lapitinib and exerted 
antagonistic effects on cell proliferation in a few cell lines. Examining the effect of combination of 
fucoidan from Fucus evanescence with cyclophosphamide, 7 out of 10 mice that were injected with  
25 mg/kg/body weight fucoidan plus cyclophosphamide died whereas of the mice that were treated 
with fucoidan alone, 3 out of 10 died [66]. 
Fucoidan has been examined in several clinical trials mainly for its anti-coagulant and anti-viral 
properties. Administration of capsules containing 560 mg fucoidan from Undaria pinnatifida for up to  
24 months did not induce any side effect when the participants took 4 capsules a day [75]. In  
Mori et al. [76] and Irhimeh et al. [77] studies, daily consumption of 5 capsules contained 166 mg 
fucoidan from C okamuranus Tokida for over one year and 3 g HMW fucoidan from Undaria 
pinnatifida for up to 12 days, respectively, were revealed to be safe. However, Irhimeh et al. 
demonstrated that orally administered fucoidan affected coagulation tests and prolonged the aPTT, 
thrombin time and AT-III. Other studies have also shown the potential of bleeding complication 
development due to fucoidan’s anti-thrombotic property [78]. Diarrhea is another reported side effect, 
which was seen in 4 out of 17 participants within 1 month of daily administration of 6 g fucoidan [79]. 
When a blend of three different extracts (from Fucus vesiculosis (85% w/w), Macrocystis pyrifera 
(10% w/w), and Laminaria japonica (5% w/w)) in capsules containing up to 187.5 mg were daily 
given to volunteers, a statistically significant change in the potassium level was seen after 28 days. 
Although, the change was minor and within the clinical reference range [80]. 
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4. Conclusions 
The goal of cancer treatment is eradication of tumor cells ideally with minimal damage to healthy 
tissues. Because of the side-effects of many current treatments, the use of natural substances of low toxicity 
is of interest. A number of in vitro and in vivo studies have indicated that fucoidan contains strong  
anti-cancer bioactivity. Since fucoidan also possesses immunomodulatory effects, it is postulated that it 
may have protective effects against development of side effects when it is co-administered with 
chemotherapeutic agents and radiation.  
In this report, we reviewed the underlying cellular mechanisms by which fucoidan induces cell 
death within tumor cells and increases the survival rate of tumor-bearing animal models by 
suppression of metastasis and angiogenesis. However despite numerous promising pre-clinical reports, 
there are few reported clinical studies so far [61]. In this review we also discussed the challenges 
impeding utilization of fucoidan in the clinic which include the complex heterogeneous structure of 
fucoidan, highly variable doses, different administration routes and possible negative interactions with 
chemotherapy. Due to the wide variation of fucoidan structure and to make future experiments 
reproducible, it is recommended that the critical bioactivity factors such as fucoidan content, sulfate 
content, monosaccharide constituents and molecular weight be reported. Attention to these factors will 
be likely to lead to more consistent reports and ultimately produce the required evidence to underpin 
clinical studies in near future. 
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